Literature DB >> 19853976

Synthesis, anticonvulsant activity and 3D-QSAR study of some prop-2-eneamido and 1-acetyl-pyrazolin derivatives of aminobenzothiazole.

Nikhil D Amnerkar1, Kishore P Bhusari.   

Abstract

A series of 6-substituted-[3-substituted-prop-2-eneamido]benzothiazole 9-32 and 6-substituted-2-[(1-acetyl-5-substituted)-2-pyrazolin-3-yl]aminobenzothiazole 33-56 were synthesized using appropriate synthetic route and evaluated experimentally against maximal electroshock test. Selected compounds were evaluated for neurotoxicity, hepatotoxicity and behavioral study. The most active compound, 6-methyl-2-[(1-acetyl-5-(4-chlorophenyl))-2-pyrazolin-3-yl]aminobenzothiazole 52 exhibited an ED50 of 25.49 micromol/kg, TD50 of 123.87 micromol/kg and high protective index (PI) of 4.86 compared to standard drug phenytoin. The 3D-QSAR analysis was carried out by PHASE program and a statistically reliable model with good predictive power (r2=0.9220, q2=0.8144) was achieved. The 3D-QSAR plots illustrated insights into the structure activity relationship of these compounds which may aids in the design of potent aminobenzothiazole derivatives as anticonvulsant agents. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853976     DOI: 10.1016/j.ejmech.2009.09.037

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  15 in total

1.  (2E)-3-(1,3-Diphenyl-1H-pyrazol-4-yl)-1-phenyl-prop-2-en-1-one.

Authors:  Hoong-Kun Fun; Madhukar Hemamalini; Shridhar Malladi; Pradeep Poojari; Arun M Isloor
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-06-18

2.  (2E)-1-(2,4-Dichloro-phen-yl)-3-[3-(4-nitro-phen-yl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one.

Authors:  Arun M Isloor; Shridhar Malladi; Thomas Gerber; Benjamin van Brecht; Richard Betz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-02-04

3.  (E)-1-(2,4-Dichloro-phen-yl)-3-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-en-1-one.

Authors:  Hoong-Kun Fun; Ching Kheng Quah; Shridhar Malladi; Arun M Isloor; Kammasandra N Shivananda
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-10-29

4.  Pharmacophore Modelling and 3D-QSAR Studies on N(3)-Phenylpyrazinones as Corticotropin-Releasing Factor 1 Receptor Antagonists.

Authors:  Paramjit Kaur; Vikas Sharma; Vipin Kumar
Journal:  Int J Med Chem       Date:  2012-05-31

Review 5.  From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.

Authors:  Serge Mignani; Jean-Pierre Majoral; Jean-François Desaphy; Giovanni Lentini
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

6.  Synthesis and Herbicidal Activity of 5-Heterocycloxy-3-methyl-1-substituted-1H-pyrazoles.

Authors:  Jing Kang; Xia Li Yue; Chang Shui Chen; Jian Hong Li; Hong Ju Ma
Journal:  Molecules       Date:  2015-12-25       Impact factor: 4.411

7.  Synthesis, Computational Studies and Anticonvulsant Activity of Novel Benzothiazole Coupled Sulfonamide Derivatives.

Authors:  Sukhbir L Khokra; Kanika Arora; Shah A Khan; Pawan Kaushik; Reetu Saini; Asif Husain
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

8.  One-pot synthesis of 2'-aminobenzothiazolo-arylmethyl-2-naphthols catalyzed by NBS under solvent-free conditions.

Authors:  Wei Lin Li; Li Li Wang; Qiu Yan Luo
Journal:  ScientificWorldJournal       Date:  2013-05-30

Review 9.  Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.

Authors:  Dimitris Matiadis; Marina Sagnou
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

10.  Design, Synthesis and Anticancer Screening of Novel Benzothiazole-Piperazine-1,2,3-Triazole Hybrids.

Authors:  Mohamed R Aouad; Moataz A Soliman; Muath O Alharbi; Sanaa K Bardaweel; Pramod K Sahu; Adeeb A Ali; Mouslim Messali; Nadjet Rezki; Yaseen A Al-Soud
Journal:  Molecules       Date:  2018-10-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.